Skip to content
eHealthTutorial — Research Peptide Reviews
Experimental • Not FDA-approved

Delta sleep-inducing peptide research

DSIP (Emideltide)

DSIP, also called emideltide, is a short peptide historically investigated in sleep studies. Its suggestive small human experiments do not establish an insomnia treatment or the safety of a research vial.

Open calculator Explore the research
Generic research visual — not a commercial product
Compound typeSynthetic nine-amino-acid peptide
Evidence baseVery small, older human sleep experiments
Regulatory contextInvestigational / Not FDA-approved
Page purposeResearch and calculation

Compound calculator

DSIP (Emideltide) reconstitution calculator

Enter the values printed on your vial and the liquid volume you added to calculate concentration, liquid volume, and the corresponding mark on a U-100 syringe scale.

Selected peptide or compoundDSIP (Emideltide)
Enter the total amount printed on the vial.
mL
Enter the liquid volume added in milliliters.
You provide this amount; the calculator does not select or recommend it.
Scale reference only; confirm the markings on the physical syringe.

Your DSIP (Emideltide) calculation appears here

Enter the three required values to see the mathematical result.

This calculator performs arithmetic using values you enter. It does not select or recommend an amount, schedule, treatment, preparation method, or method of administration.

Research overview

What is DSIP (Emideltide)?

“Delta sleep-inducing peptide” is the historic DSIP name for emideltide, a nine-residue peptide. The name reflects an early research hypothesis, not proof that a labeled product induces healthy sleep or treats insomnia. Free-base and acetate forms are separately discussed in FDA’s compounding context.

What has research examined?

An early double-blind crossover study involved just six healthy volunteers and measured acute and later sleep parameters. Another small study examined six people with disturbed sleep. Such small samples and old designs do not determine a reliable clinical effect or long-term safety. FDA notes possible immunogenicity and peptide-impurity characterization concerns for compounded emideltide and reports insufficient safety information for proposed administration routes.

Important limitation

Experiments with six participants cannot establish a sleep-disorder treatment. FDA’s proposed-route safety information is inadequate; neither the old study procedures nor supplier labels validate a vial’s identity, preparation, or use. This page provides arithmetic only from user-entered values.

Research references

Calculation boundary

The calculator performs concentration arithmetic only when a user enters a mass and liquid volume. It does not verify identity, formulation, purity, sterility, stability, compatibility, biological-unit equivalence, or whether reconstitution applies to a particular product. Do not convert IU or other biological units to mg without an authoritative, exact-product relationship.

For research purposes only. This page is educational and is not medical or veterinary advice or a recommendation to purchase, prepare, administer, or use any product.